Skip to main content
COVID-19 In Vitro Diagnostic Devices and Test Methods Database

COVID-19 In Vitro Diagnostic Medical Device - detail

SARS-CoV-2/Influenza A+B/RSV Antigen Combo Rapid Test (Nasopharyngeal Swab)

Manufactured by Acro Biotech Inc, United States - www.acrobiotech.com 

Device identification number
2397
CE Marking
Yes
HSC common list (RAT)
×No
Format
Near POC / POC
Physical Support
Cassette, Lateral flow
Target type
Antigen
Specimen
Nasopharyngeal swab
Cross-reactivity (pathogens tested)
Adenovirus 3, Adenovirus 7, Alpha Coronavirus 229E (HCoV-229E), Alpha Coronavirus Nl63 (HCoV-Nl63), Beta Coronavirus HKU1 (HCoV-HKU1), Beta Coronavirus OC43 (HCoV-OC43), Parainfluenza Virus Type 2, Parainfluenza Virus Type 3
Lineages detected
A.23.1 AT.1 B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427 (Epsilon), B.1.429 (Epsilon), B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3 B.1.621 (Mu), C.36 P.1 (Gamma), P.2 (Zeta), P.3 (Theta), C.37 (Lambda), B.1.616 B.1.526.1 B.1.526.2
Commercial Status
Commercialised
Last Update
2022-04-20 12:09:38 CET
Comments
The SARS-CoV-2/Influenza A+B/RSV Antigen Combo Rapid Test (Nasopharyngeal Swab) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus(RSV) antigens in nasopharyngeal swab specimens from individuals with suspected SARS-CoV-2/Influenza/RSV infection in conjunction with clinical presentation and the results of other laboratory tests. Results are for the detection of SARS-CoV-2, Influenza A+B and RSV Antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out other bacterial/viral infection. The agent detected may not be the definite cause of disease. Negative results do not preclude SARS-CoV-2/Influenza A+B/RSV infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, Influenza A+B and RSV. The SARS-CoV-2/Influenza A+B/RSV Antigen Combo Rapid Test is intended for use by trained clinical laboratory personnel.
Assay Type
Immuno-Antigen
Subcategory
Validity test kit
Method
Immunoassay
Measurement
Qualitative
Time
15 minutes
Subclass
Sandwich
LOD
100 AU
Calibration
Evaluated
Crossreactivity
Evaluated
Fp
0.051 AU ((RSV Test).)
Fp
0.023 AU ((SARS-CoV-2 Test);)
Fp
0.054 AU ((Influenza Type B);)
Fp
0.03 AU ((Influenza Type A);)
Fn
0.01 AU ((SARS-CoV-2 Test);)
Fn
0.016 AU ((RSV Test).)
Fn
0.006 AU ((Influenza Type B);)
Fn
0.006 AU ((Influenza Type A);)
Precision
Evaluated
Accuracy
99.2 % ((Antigen)(Influenza Type A);)
Accuracy
99 % ((Antigen)(Influenza Type B);)
Accuracy
97.9 % ((Antigen)(RSV Test).)
Accuracy
98.6 % ((Antigen)(SARS-CoV-2 Test);)
Reproducibility
Evaluated
Robustness
Evaluated
Clinical Sensitivity
97.7 % ((Antigen)(SARS-CoV-2 Test);)
Clinical Sensitivity
97 % ((Antigen)(Influenza Type A);)
Clinical Sensitivity
94.6 % ((Antigen)(Influenza Type B);)
Clinical Sensitivity
94.9 % ((Antigen)(RSV Test).)
Clinical Specificity
99 % ((Antigen)(SARS-CoV-2 Test);9)
Clinical Specificity
9.4 % ((Antigen)(Influenza Type A);)
Clinical Specificity
99.4 % ((Antigen)(Influenza Type B);)
Clinical Specificity
98.4 % ((Antigen)(RSV Test).)
Type of antigen
Nucleoprotein

The database contains publicly available In Vitro Diagnostic Medical Devices for COVID-19 and it is being updated periodically. Please note that additional performance (as retrieved from manufacturers web pages) is provided only for devices commercially available with CE-IVD mark. Acknowledgements